01875

3.3751.50%
JL

Jincai Li

Executive Chairman of the Board

Dr. Jincai Li, Ph.D., also known as Jimmy, was Executive Director of BioDlink International Company Limited from April 29, 2026 to 2026 and serves as Executive Chairman of the Board from 2026. He serves as Chief Executive Officer of WuXi XDC Cayman Inc. since June 2023 and served as its Director since December 2020. He serves as an Executive Director of WuXi XDC Cayman Inc. since June 30, 2023. He was Senior Vice President of WuXi Biologics (Cayman) Inc. until 2024 and served as its Chief Executive Officer of WuXi XDC until 2024. Dr. Li has experience in biologics process development, scale-up and cGMP manufacturing. Under his leadership, Group became a leading ADC and bioconjugates CRDMO, which was recognized by the 2022 World ADC Awards’ Runner Up prize in the “Best CMO Provider” category and the winner of the 2023 World ADC Awards’ prize in the “Best Contract Development Manufacturing Organization (CDMO)” category. Dr. Li joined the WXB Group in September 2011 and since May 2020 had served as the senior vice president at the WXB Group. Throughout 2021 and 2022, Dr. Li spearheaded the integration of the ADC capabilities into our Group and accumulatively his team had completed more than 40 ADCs/bioconjugates IND filings in China, US and Europe. From September 2011, Dr. Li built and led the cell culture process development and non-GMP pilot plant production group of the WXB Group and went on to manage the MFG1, MFG3 cGMP facilities, as well as the start-up of the MFG5 cGMP facility. During his tenure with MFG1, Dr. Li led the efforts to successfully pass our first FDA and EMA pre-license inspections and achieved the first FDA biologics BLA approval in China. Before Dr. Li joined the WXB Group, from August 2007 to September 2011, Dr. Li had also served as a group leader at Genentech, Inc. where he was responsible for cell culture process development. From April 2006 to July 2007, Dr. Li had also been a scientist at Tanox, Inc. and from August 2001 to March 2006, Dr. Li was a staff scientist at Diversa Corporation (now BASF) where he was in charge of process development for multiple biologics projects. Dr. Li obtained a bachelor’s degree in chemical engineering and technology and minor in chemistry from Tsinghua University in China in July 1996 and obtained a doctoral degree majoring in chemical and biochemical engineering from University of Maryland Baltimore County in the United States in August 2001.

Positions